Sponsored by

​36 Duchenne experts sign UCLA letter in support of approval of Sarepta’s drug

The letter was delivered to the FDA’s Division of Neurology Products last month, but was just posted on the UCLA’s website this morning.

​Cancer drug deal between Harvard, Merck skips the startup phase

The Blavatnik Biomedical Accelerator at Harvard has announced a license and collaboration agreement with New Jersey-based Merck & Co.

​Thermo Fisher fights back vs. rival bid in $1.3B Affymetrix acquisition

Last week a firm called Origin Technologies Corp. made up largely of former executives at Affymetrix, attempted to outbid Thermo.

Spring Bank Pharmaceuticals postpones $40M IPO

The Milford-based biotech firm was expected to offer 2.9 million shares this week at between $13 and $15.

Monday's Clinton fundraiser isn't at Theranos, after all

OHSU scientists: Antibodies could clear HIV in infants